The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results